Control Bionics Ltd (CBL) - Total Liabilities
Based on the latest financial reports, Control Bionics Ltd (CBL) has total liabilities worth AU$2.20 Million AUD (≈ $1.56 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Control Bionics Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Control Bionics Ltd's total liabilities have evolved over time, based on quarterly financial data. See CBL working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Control Bionics Ltd Competitors by Total Liabilities
The table below lists competitors of Control Bionics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Les Enphants Co Ltd
TW:2911
|
Taiwan | NT$2.86 Billion |
|
Inmobiliaria Park Rose Iberoamericana SOCIMI SA
MC:YPARK
|
Spain | €11.04 Million |
|
Tulikivi Oyj A
HE:TULAV
|
Finland | €19.10 Million |
|
Inventec Besta Co Ltd
TW:8201
|
Taiwan | NT$176.56 Million |
|
AGMO
KLSE:0258
|
Malaysia | RM7.43 Million |
|
BIONXT SOLUTIONS INC.
F:BXT
|
Germany | €9.54 Million |
|
Strategic Metals Ltd
V:SMD
|
Canada | CA$4.05 Million |
|
Coal Energy S.A.
WAR:CLE
|
Poland | zł3.83 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Control Bionics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CBL stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Control Bionics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Control Bionics Ltd (2014–2024)
The table below shows the annual total liabilities of Control Bionics Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | AU$2.72 Million ≈ $1.93 Million |
-1.28% |
| 2023-12-31 | AU$2.76 Million ≈ $1.95 Million |
+74.65% |
| 2022-12-31 | AU$1.58 Million ≈ $1.12 Million |
+4.47% |
| 2021-12-31 | AU$1.51 Million ≈ $1.07 Million |
+27.07% |
| 2020-12-31 | AU$1.19 Million ≈ $842.14K |
+207.54% |
| 2019-12-31 | AU$387.00K ≈ $273.83K |
+2.98% |
| 2018-12-31 | AU$375.80K ≈ $265.90K |
+74.08% |
| 2017-12-31 | AU$215.88K ≈ $152.75K |
-99.98% |
| 2016-12-31 | AU$876.38 Million ≈ $620.10 Million |
+69.81% |
| 2015-12-31 | AU$516.09 Million ≈ $365.17 Million |
+19.03% |
| 2014-12-31 | AU$433.58 Million ≈ $306.78 Million |
-- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more